V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Aclaris Therapeutics Executive Compensation (FY25)

ACRS · Executive and director compensation, fiscal 2025 only
Data as of September 7, 2026Latest filing (8-K): June 4, 2026
145 figures on this page: 139 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
Neal Walker was paid $3,375,591 in total compensation as Chief Executive Officer for fiscal 2025, and the fiscal 2025 disclosure covers 3 named executive officers. Meanwhile, the say-on-pay proposal drew 89.5% support at the meeting held June 4, 2026 for fiscal 2025. The compensation disclosed runs fiscal 2025 only.
Chief executive, fiscal 2025
◇
Neal Walker
Latest say-on-pay support
=
June 4, 2026

Frequently asked questions

Answers drawn from the data on this page.
Who is Aclaris Therapeutics' chief executive and what were they paid?
Neal Walker was paid $3,375,591 in total compensation as Chief Executive Officer for fiscal 2025.
What was Aclaris Therapeutics' say-on-pay result?
The say-on-pay proposal drew 89.5% support at the meeting held June 4, 2026 for fiscal 2025.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Neal Walker
Chief Executive Officer
◇—◇◇◇——◇
Kevin Balthaser
Chief Financial Officer
◇—◇◇◇—◇◇
James Loerop
Chief Business Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
James LoeropOPTION◇——◇——◇
James LoeropRSU◇——◇——◇
James LoeropRSU◇——◇——◇
Kevin BalthaserRSU◇——◇——◇
Kevin BalthaserOPTION◇——◇——◇
Kevin BalthaserRSU◇——◇——◇
Neal WalkerRSU◇——◇——◇
Neal WalkerOPTION◇——◇——◇
Neal WalkerRSU◇——◇——◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
James LoeropRSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Kevin BalthaserRSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
Neal WalkerOption◇—◇—
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Molineaux
Lead independent director
◇◇◇——◇◇
Vincent Milano
◇◇◇——◇◇
Anand Mehra
◇◇◇——◇◇
William Humphries
◇◇◇——◇◇
Andrew Schiff
◇◇◇——◇◇
Maxine Gowen, Neal Walker and Hugh Davis served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 4, 2026=◇◇◇
2024June 5, 2025=◇◇◇
2023June 6, 2024=◇◇◇
2022June 1, 2023=◇◇◇
2021June 2, 2022=◇◇◇
2020June 3, 2021=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Aclaris Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Aclaris Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Aclaris Therapeutics' disclosed peer group is defensible, who names Aclaris Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
145 figures on this page: 139 cited to the filing that reported them, 6 calculated from figures it prints.
139 cited to the filing
6 calculated from the filing

Documents cited

  1. 0001104659-26-070494
  2. 0001104659-26-047262
    Director Compensation Table · EXECUTIVE COMPENSATION · NON-EMPLOYEE DIRECTOR COMPENSATION · Outstanding Equity Awards as of December 31, 2025 · and 2 more sections
  3. 0001558370-25-008430
  4. 0001558370-24-009009
  5. 0001558370-23-010763
  6. 0001558370-22-009718
  7. 0001558370-21-007977
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Aclaris Therapeutics executive compensation, FY2025.” https://intel.velarion.ai/comp/ACRS (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Aclaris Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy